Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

February 11, 2025 11:30 ET | Source: Lycia Therapeutics, Inc.

Lycia Therapeutics Announces the Appointment of Chin Lee, MD, MPH, as Chief Medical Officer and Reveals Immunology Pipeline

Lycia Therapeutics Announces the Appointment of Chin Lee, MD, MPH, as Chief Medical Officer and Reveals Immunology Pipeline
April 04, 2011 09:00 ET | Source: Neothetics

Lithera, Inc. Appoints Thomas Wiggans to Board of Directors

SAN DIEGO, April 4, 2011 (GLOBE NEWSWIRE) -- Lithera, Inc. announced today the appointment of Thomas G. Wiggans to its Board of Directors. "Lithera is making substantial progress with LIPO-102 by...
March 21, 2011 09:00 ET | Source: Neothetics

Lithera Announces the Appointment of George W. Mahaffey as President and Chief Executive Officer

SAN DIEGO, March 21, 2011 (GLOBE NEWSWIRE) -- Lithera, Inc. today announced the appointment of George W. Mahaffey as President and Chief Executive Officer. Mr. Mahaffey will also join the Lithera...
November 03, 2010 09:00 ET | Source: Neothetics

Lithera Reports Positive Clinical Study Results From a Phase IIb Trial for LIPO-102, a Novel Treatment for Localized Fat Reduction

SAN DIEGO, Nov. 3, 2010 (GLOBE NEWSWIRE) -- Lithera, Inc. today announced positive results from a Phase IIb clinical study of LIPO-102, its novel injectable combination of salmeterol xinafoate (SX)...
October 12, 2010 09:00 ET | Source: Neothetics

Lithera Announces Notice of Allowance for a Key Patent Application for LIPO-102, a Novel Treatment for Localized Fat Reduction

SAN DIEGO, Oct. 12, 2010 (GLOBE NEWSWIRE) -- Lithera, Inc. today announced receipt of a Notice of Allowance from the U.S. Patent and Trademark Office for a patent application broadly covering...
May 05, 2010 09:00 ET | Source: Neothetics

Lithera Reports Positive Clinical Study Results From a Second Phase IIa Trial for LIPO-102, a Novel Treatment for Localized Fat Reduction

SAN DIEGO, May 5, 2010 (GLOBE NEWSWIRE) -- Lithera, Inc. today announced positive results from a Phase IIa clinical study of LIPO-102, its novel injectable combination of salmeterol xinafoate (SX) and...
March 09, 2010 09:00 ET | Source: Neothetics

Lithera Reports Positive Phase IIa Clinical Study Results for LIPO-102, a Novel Treatment for Localized Fat Reduction

SAN DIEGO, March 9, 2010 (GLOBE NEWSWIRE) -- Lithera, Inc. today announced positive results from a Phase IIa clinical study of LIPO-102, its novel injectable combination of salmeterol xinafoate (SX)...
February 23, 2010 09:00 ET | Source: Neothetics

Lithera Obtains Orphan Drug Product Designation for LIPO-102

SAN DIEGO, Calif., Feb. 23, 2010 (GLOBE NEWSWIRE) -- Lithera, Inc. today announced the receipt of Orphan Drug Product Designation for LIPO-102 for the treatment of symptomatic exophthalmos associated...
February 09, 2010 09:00 ET | Source: Neothetics

Lithera Successfully Completes Phase I Clinical Trial of LIPO-102

SAN DIEGO, Feb. 9, 2010 (GLOBE NEWSWIRE) -- Lithera, Inc. today announced the successful completion of a three-part Phase I clinical trial of LIPO-102 being developed for the treatment of...